Opdivo (nivolumab): Insurance Coverage and Denials
A plain-language guide to PD-1 immune checkpoint inhibitor coverage, why insurers deny it, and where to get cancer-specific help.
Opdivo is an immunotherapy classified as a PD-1 blocking antibody. Like other checkpoint inhibitors, it interrupts the PD-1 signaling pathway that tumors exploit to suppress immune T cells, helping the immune system recognize and attack cancer. The FDA has approved Opdivo, alone or in combination, across multiple cancers including certain melanoma, non-small cell lung, renal cell, classical Hodgkin lymphoma, head and neck, urothelial, and gastrointestinal cancers, frequently tied to tumor type, prior treatment, or biomarker criteria.
Insurers commonly require prior authorization and often scrutinize the line of therapy, whether Opdivo is used as a single agent or in combination, and whether biomarker or histology requirements are met. Delays can stem from site-of-care infusion policies or requests for additional clinical documentation.
If coverage is denied, you generally have the right to an internal appeal followed by an independent external review under federal protections such as 45 CFR 147.136. For specialized cancer support, reach out to the PAN Foundation, Patient Advocate Foundation, Triage Cancer, CancerCare, or Bristol Myers Squibb's BMS Access Support copay and assistance programs.
Where to get cancer-specific help
A note on scope. Apellica focuses on appeals for non-oncology insurance denials and does not handle cancer-related appeal cases. Cancer coverage involves complex, fast-moving clinical and financial questions, and patients are best served by organizations built specifically for oncology. If you are facing a cancer drug denial, please reach out to the specialized groups listed on this page, including the PAN Foundation, the Patient Advocate Foundation, Triage Cancer, and CancerCare, along with the manufacturer's own copay or patient-assistance program. They offer free, expert, cancer-focused support, and they can help you understand your options and protect your access to treatment. ---
- PAN Foundation Copay and financial assistance funds for specific diagnoses.
- Patient Advocate Foundation Case managers who help with insurance denials and appeals for serious illness.
- Triage Cancer Free education and resources on cancer-related insurance and appeals.
- CancerCare Professional support services and financial assistance.
Oncology clinics and manufacturers
Apellica partners with infusion centers, oncology practices, and pharmaceutical manufacturers on denial recovery and patient access at scale. If you are exploring a partnership, we would like to talk.
Partner with usFrequently asked questions
- Why do insurers deny Opdivo?
- Prior authorization criteria not met; Combination-therapy or sequencing rules; Site-of-care restrictions; Biomarker documentation.
- Can I appeal a Opdivo denial?
- Yes. You generally have the right to an internal appeal and then an independent external review under federal rules such as 45 CFR 147.136. For cancer-specific help, the organizations listed on this page specialize in oncology coverage.